Positive Media Coverage Somewhat Unlikely to Impact Biohaven Pharmaceutical (NYSE:BHVN) Share Price

Headlines about Biohaven Pharmaceutical (NYSE:BHVN) have trended positive on Tuesday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biohaven Pharmaceutical earned a news impact score of 0.26 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.3698545684344 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern’s scoring:

How to Become a New Pot Stock Millionaire

NYSE BHVN traded up $0.57 during mid-day trading on Tuesday, hitting $25.10. The stock had a trading volume of 760,076 shares, compared to its average volume of 774,895. Biohaven Pharmaceutical has a twelve month low of $16.50 and a twelve month high of $39.51. The company has a market cap of $927.81 and a P/E ratio of -5.02.

BHVN has been the topic of a number of recent analyst reports. Piper Jaffray reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Monday, March 26th. Canaccord Genuity reissued a “buy” rating and issued a $34.00 price objective (down from $39.00) on shares of Biohaven Pharmaceutical in a research note on Monday, March 26th. Zacks Investment Research raised Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Friday, March 9th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $37.86.

In other Biohaven Pharmaceutical news, insider Robert Berman sold 35,000 shares of the firm’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $27.52, for a total value of $963,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Portage Biotech Inc. sold 35,650 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $28.61, for a total value of $1,019,946.50. Following the completion of the sale, the insider now directly owns 124,371 shares of the company’s stock, valued at $3,558,254.31. The disclosure for this sale can be found here. Insiders sold a total of 783,546 shares of company stock valued at $22,591,021 over the last ninety days.

TRADEMARK VIOLATION WARNING: This report was originally published by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://baseballnewssource.com/2018/04/03/favorable-press-coverage-somewhat-unlikely-to-affect-biohaven-pharmaceutical-bhvn-stock-price/2018465.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.